Track topics on Twitter Track topics that are important to you
Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.
Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.
Original Article: Avacta Group Plc making 'excellent progress' on lead programmesNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...